Feature | January 14, 2014

Boston Scientific Invests in Bioresorbable Stent Startup Amaranth Medical

cath lab stents bioresorbable amaranth fortitude scaffold

January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The additional investment capital will be used to advance the clinical development of the Amaranth Fortitude drug-eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE marking. In addition, the funding will support continued development of the next-generation Fortitude bioresorbable scaffold, which will have thinner struts than any currently available polymeric bioresorbable scaffold.
 
"The properties of the proprietary polymer and the unique manufacturing processes that we developed have allowed us to produce a scaffold with mechanical strength and durability which we believe exceeds that of all currently available bioresorbable scaffolds,” said Kamal Ramzipoor, CEO, Amaranth.
 
The non-drug-eluting Fortitude scaffold was previously evaluated in a study of 13 patients with symptomatic coronary artery disease (CAD), results of which were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting Oct. 27, 2013. The data suggested that the Fortitude scaffold maintained its mechanical integrity, with late lumen loss comparable to that observed with bare metal stents
 
The scaffold is designed to afford the strength of metal stents to assist the artery during the remodeling process following an interventional procedure, without leaving behind a permanent implant with inherent clinical limitations.
 
In 2014, Amaranth will begin enrolling a second cohort of patients to evaluate a drug-eluting Fortitude scaffold.
 
For more information: www.amaranthmedical.com

Related Content

News | Stents

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
News | Stents

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
News | Stents

April 6, 2022 – Narrowed arteries can restrict blood flow to the heart. One treatment is inserting a stent — a small ...

Home April 06, 2022
Home
News | Stents

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...

Home November 09, 2021
Home
News | Stents

June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...

Home June 30, 2021
Home
News | Stents

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

Home April 14, 2021
Home
News | Stents

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

Home April 06, 2021
Home
News | Stents

December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that ...

Home December 21, 2020
Home
News | Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

Home November 24, 2020
Home
Feature | Stents | Dave Fornell, Editor

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
Subscribe Now